During embryogenesis and early development and shortly after seeding airway epithelial cultures, airway cells possess primary cilia ([@r1], [@r2]). These single cilia are essential for canonical vertebrate hedgehog (HH) signaling ([@r3], [@r4]). The sonic hedgehog (SHH) ligand is a morphogen that guides development of the lung, regulating pulmonary branching and mesenchyme differentiation ([@r5][@r6][@r7][@r8]--[@r9]). The receptor/effector system for the HH signaling pathway is complex and involves patched 1 (PTC1), smoothened (SMO), suppressor of fused (SUFU), and the glioma zinc-finger transcription factors GLI1, GLI2, and GLI3 ([@r10]).

After development is completed, airway epithelia continue to produce SHH ([@r11][@r12]--[@r13]). SHH is present on the basolateral side of the epithelia, where it signals to primary cilia on mesenchymal cells, restraining their proliferation ([@r12]). This paracrine pathway signals via canonical HH signaling to regulate expression of GLI1 in the mesenchyme. SHH is also present on the apical side of the epithelia in the thin layer of liquid covering the epithelial surface ([@r11], [@r13], [@r14]). However, mature airway epithelia lack primary cilia. As the epithelia polarize and mature, primary cilia disappear, and the cells develop numerous motile cilia on the apical surface ([@r1], [@r2]).

These observations raise the question of whether SHH has apical receptors and what their function might be. Previous studies showed that motile cilia on respiratory epithelia not only perform mechanical work, but also perform sensory functions like primary cilia ([@r15], [@r16]). These findings led us to hypothesize that motile cilia might participate in HH signaling. To test this hypothesis, we studied airway epithelia using human cells because of potential differences in cell-type distribution and HH signaling across species ([@r17], [@r18]), and because HH signaling has been reported to contribute to human lung disease, including interstitial pulmonary fibrosis, chronic obstructive pulmonary disease, and small-cell lung carcinoma ([@r19][@r20][@r21]--[@r22]). We examined differentiated primary cultures of human tracheal/bronchial epithelia grown at the air--liquid interface.

Results {#s1}
=======

HH Signaling Components Are Located in Airway Motile Cilia. {#s2}
-----------------------------------------------------------

To address the hypothesis that HH signaling involves motile cilia and ciliated airway epithelial cells, we first tested for components of the HH signaling pathway. Human airway epithelia expressed mRNA transcripts for *SHH* ([Fig. S1*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Immunostaining revealed SHH in ciliated airway epithelial cells, located beneath the apical membrane and along the upper lateral membrane ([Fig. 1](#fig01){ref-type="fig"}). We detected SHH in airway surface liquid (ASL) and basolateral medium ([Fig. S1 *B* and *C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Although the rate of basolateral secretion exceeded apical secretion, the apical SHH concentration was high because of the small volume of liquid. Whether SHH is secreted directly into the basolateral medium and whether basolateral accumulation reflects SHH movement down a concentration gradient remain unknown. These results are consistent with previous reports that ciliated airway epithelial cells produce SHH and that the ligand is present both apically and basolaterally ([@r11][@r12][@r13]--[@r14], [@r20]).

![SHH is expressed in ciliated airway epithelial cells. Images in this and other figures are from primary cultures of differentiated human airway epithelia, except in [Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental), which is lung tissue. (*A*) Section of periodic acid Schiff-stained epithelia. (*B*) Immunostaining of acetylated α-tubulin (red), SHH (green), and DAPI (nuclei, blue). *Upper* images are stacks of *X-Y* confocal images, and *Lower* images are *X-Z* images. (Scale bars, 10 μm.)](pnas.1719177115fig01){#fig01}

The presence of SHH in apical liquid suggested that it might signal to airway epithelia. Therefore, we tested for components of the HH signaling pathway and found transcripts of *PTC1*, *SMO*, *SUFU*, and the glioma zinc-finger transcription factors *GLI2* and *GLI3* ([Fig. S1*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). *GLI1* transcripts were detected, but only at very low levels. Moreover, we did not detect GLI1 by immunostaining ([Fig. S2 *A* and *B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)), consistent with previous reports ([@r12]). Immunostaining revealed PTC1 located along the length of motile cilia ([Fig. 2*A*](#fig02){ref-type="fig"} and [Fig. S3*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)), which is similar to its location in primary cilia ([@r23]). We detected lower levels of patched 2 (PTC2), also in cilia ([Fig. S2 *C* and *D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). SUFU also localized to cilia, and immunostaining was most prominent distally, consistent with reports that it sits in the distal portion of primary cilia ([@r24]) ([Fig. 2*B*](#fig02){ref-type="fig"} and [Fig. S3*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). In addition, we identified SMO, GLI2, and GLI3 in motile cilia, where they displayed discrete punctate patterns ([Fig. 2 *C*--*E*](#fig02){ref-type="fig"} and [Fig. S3 *C*--*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)), similar to their reported localization in primary cilia ([@r25], [@r26]). All of these HH signaling components were expressed in ciliated but not nonciliated cells. Overexpressed SMO confirmed its location in motile cilia ([Fig. S3*F*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Human lung tissue also revealed PTC1, SMO, and GLI2 in motile cilia ([Fig. S4 *A*--*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)).

![HH signaling proteins are present in airway motile cilia. Staining of acetylated α-tubulin is red, and staining of other immunolabeled proteins is green. Immunostaining is for PTC1 (*A*), SUFU (*B*), SMO (*C*), GLI2 (*D*), and GLI3 (*E*). *Lower* images are expanded images from *Upper*. \[Scale bars: 2 μm (*Upper*), 1 μm (*Lower*).\]](pnas.1719177115fig02){#fig02}

Airway epithelial cells have ∼150 motile cilia; two readers counted 147 ± 7 and 160 ± 18 cilia per cell (*n* = 17 cells). In contrast, cells that have primary cilia have only that one cilium ([Fig. S5*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)) ([@r27][@r28][@r29]--[@r30]). Motile cilia have axonemes with nine microtubule doublets around the circumference and two central microtubules: a "9 + 2" axoneme ([@r1], [@r29]). Primary cilia generally lack the two central microtubules: a "9 + 0" axoneme. Airway epithelial cilia exhibit a 9 + 2 structure ([@r29]). By transmission electron microscopy, we examined ∼10,000 airway cilia (i.e., the equivalent of ∼65 cells). We found none with a 9 + 0 axoneme ([Fig. S5*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). These results agree with previous observations ([@r1], [@r2], [@r29]), and we are not aware of reports that mature airway epithelia have cilia with a 9 + 0 axoneme. Therefore, it is exceedingly likely that the cilia expressing PTC1, SMO, SUFU, GLI2, and GLI3 are motile cilia with a 9 + 2 axoneme. Thus, these data suggest that motile cilia have HH signaling components that might serve as receptors and effectors for SHH in the apical airway liquid.

Airway Motile Cilia Have cAMP Signaling Components. {#s3}
---------------------------------------------------

In canonical HH signaling, SHH binds its transmembrane receptor, PTC1, relieving inhibition of the G protein-coupled receptor SMO, which signals to GLI transcription factors ([@r4], [@r25]). Immunostaining has shown that PTC1 is present in unstimulated primary cilia; adding SHH drives PTC1 to exit primary cilia, SMO then enters ([@r23]), and that induces expression of *GLI1* and *PTC1* genes ([@r31]).

Several observations suggested that canonical HH signaling was not involved in signaling by motile cilia. First, in contrast to most primary cilia, PTC1 and SMO were simultaneously present in airway motile cilia ([Fig. 3*A*](#fig03){ref-type="fig"}). Second, airway cilia and ciliated cells express very little if any GLI1 ([Figs. S1*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental) and [S2 *A* and *B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Third, applying exogenous human SHH or the SMO agonist SAG did not trigger PTC1 to exit cilia ([Fig. S6](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Fourth, neither SHH nor SAG increased *PTC1* transcripts, and *GLI1* transcripts remained very low ([Fig. S7*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Fifth, neither SHH, SAG, nor cyclopamine-KAAD affected GLI activity assessed with a GLI-luciferase reporter expressed in airway epithelia ([Fig. S7 *B* and *C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). Thus, SHH does not appear to activate the canonical HH signaling pathway in airway epithelia.

![Gα~i~ and AC5/6 are expressed with SMO in motile cilia. (*A*) Staining of SMO (green), PTC1 (red), and IFT88 (cilia, blue). (*B* and *C*) Staining of acetylated α-tubulin is red, and staining of Gα~i~ (*B*) and AC5/6 (*C*) is green. (*D* and *E*) Staining of SMO is green, staining of Gα~i~ (*D*) and AC5/6 (*E*) is red, and staining of acetylated α-tubulin is blue. *Lower* images are expanded images from *Upper*. \[Scale bars: 2 μm (*Upper*), 1 μm (*Lower*).\]](pnas.1719177115fig03){#fig03}

SHH can also signal through a noncanonical pathway to decrease intracellular cAMP levels ([@r32], [@r33]). In this context, SMO couples to Gα~i~ ([@r32], [@r33]), which inhibits adenylyl cyclase 5/6. Previous reports identified Gα~i~ and adenylyl cyclase 5/6 in primary cilia ([@r34], [@r35]). We found Gα~i~ and adenylyl cyclase 5/6 localized to airway cilia ([Fig. 3 *B* and *C*](#fig03){ref-type="fig"} and [Fig. S4*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)) in the same cilia as SMO ([Fig. 3 *D* and *E*](#fig03){ref-type="fig"}). Consistent with previous reports ([@r15]), ciliated airway epithelial cells also expressed the catalytic and regulatory subunits of cAMP-dependent protein kinase (PKA), which localized to multiple cilia and the cytoplasm ([Fig. S8](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)).

SHH Signaling Dampens cAMP-Dependent Airway Defense Functions. {#s4}
--------------------------------------------------------------

These data place SHH in a position to interact with cilia and regulate intracellular cAMP levels. To test this prediction, we measured cAMP levels in airway epithelia by ELISA. We applied a concentration in the range we observed in ASL ([Fig. S1*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)) and previously reported in vivo ([@r13]). SHH reduced cAMP levels under basal conditions and when cAMP was increased by adding forskolin and 3-isobutyl-2-methylxanthine (IBMX) ([Fig. 4*A*](#fig04){ref-type="fig"} and [Fig. S9](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). The SMO agonist SAG had a similar effect ([Fig. 4*B*](#fig04){ref-type="fig"}). Inhibiting Gα~i~ with pertussis toxin (PTX) blunted the effect of SHH ([Fig. 4*A*](#fig04){ref-type="fig"}). In addition, the SMO inhibitor, cyclopamine-KAAD, increased cAMP levels under basal conditions, but had minimal effects when cAMP levels were elevated with forskolin ([Fig. 4*B*](#fig04){ref-type="fig"}).

![SHH reduces cellular levels of cAMP. (*A*--*C*) Each dot is a measurement from epithelia from a different human donor. Bars and whiskers indicate mean ± SEM. (*A*) Data are changes in cAMP concentrations measured by ELISA in differentiated human airway epithelia. Data for basal conditions (*Left*) and data obtained 10 min after addition of forskolin (5 μM) and IBMX (100 μM) (*Right*). Data are the change in cAMP levels compared with vehicle control. For vehicle, basal cAMP level was 11 ± 2 pmol/μg, and for forskolin/IBMX, cAMP level was 219 ± 9 pmol/μg. Epithelia received apical SHH (53 nM) or SHH plus PTX (1.7 nM). *n* = 12. In *A* and *B*, compared with vehicle, \*\**P* \< 0.01 and \**P* \< 0.05 by paired Student's *t* test. In *A*, compared with SHH, ^††^*P* \< 0.01 and ^†^*P* \< 0.05 by paired Student's *t* test. (*B*) Data are changes in cAMP concentrations compared with vehicle control following apical addition of the SMO agonist SAG (200 nM) or cyclopamine-KAAD (250 nM) under basal conditions (*Left*) (*n* = 12) or with forskolin (5 μM) and IBMX (100 μM) (*Right*) (*n* = 6). For vehicle, basal cAMP level was 15 ± 2 pmol/μg and forskolin/IBMX cAMP was 201 ± 11 pmol/μg. (*C*) Change in cerulean/citrine fluorescence ratio of the FRET-based cAMP sensor in ciliated cells at the level of cilia, in the midportion of the cell, and at the basal region of the cell. Measurements in nonciliated cells in the same microscopic field are in [Fig. S10](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental). Fluorescence is reported 15 min after addition of vehicle, SHH (263 nM), or MDL-12330A (100 μM, as a positive control). Each data point is the average of two to four ciliated cells in epithelia from a different donor. \**P* \< 0.05 and \*\**P* \< 0.01 compared with vehicle by one-way repeated-measures ANOVA with Sidak multiple-comparison posttest.](pnas.1719177115fig04){#fig04}

To test for cAMP in cilia, we expressed a genetically encoded sensor of cAMP levels that localizes to cilia and also cytoplasm ([Fig. S10*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental) and [Movie S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)) ([@r36]). In ciliated epithelial cells, SHH reduced cAMP levels in the region of cilia, as did an adenylyl cyclase inhibitor MDL-12330A (a positive control) ([Fig. 4*C*](#fig04){ref-type="fig"}) ([@r35]). SHH also tended to reduce cAMP beneath cilia in the cell; a change in cytosolic levels of cAMP might result from cAMP or Gα~i~ diffusion. In contrast, SHH did not reduce cAMP levels in nonciliated cells ([Fig. S10*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)). The presence of HH signaling components in ciliated but not in nonciliated cells and a SHH-induced cAMP reduction in ciliated but not nonciliated cells suggest that SHH regulates cAMP levels via airway cilia. Nevertheless, we cannot exclude some HH signaling via receptors in nonciliated cells.

These findings suggest that HH signaling may influence physiological functions at the airway apical surface, the point of contact between the environment and the lung. Two host defenses at that site are mucociliary transport and bacterial killing by antimicrobial proteins. Previous studies showed that increasing cAMP accelerates ciliary beating ([@r37]). We found that SHH slowed cilia beat frequency (CBF), and PTX attenuated this effect ([Fig. 5*A*](#fig05){ref-type="fig"}). Conversely, cyclopamine-KAAD increased CBF under basal conditions ([Fig. 5*B*](#fig05){ref-type="fig"}).

![Apical SHH reduces CBF and ASL pH. Each set of data points is from a different donor. Bars and whiskers indicate mean ± SEM. (*A*) Change in CBF following addition of vehicle, SHH (263 nM), and SHH plus PTX (1.7 nM) under basal conditions (*Left*). Data (*Right*) are change in CBF produced by addition of forskolin (10 μM) and IBMX (100 μM) in presence of vehicle, SHH, or SHH plus PTX. Each data point is average of two to four cells. *n* = 8. \*\**P* \< 0.01 vs. vehicle and ^††^*P* \< 0.01 compared with SHH by one-way repeated-measures ANOVA with Sidak multiple-comparison posttest. (*B*) Change in CBF after addition of vehicle or cyclopamine-KAAD (250 nM) (*Left*). Data (*Right*) are change in CBF produced by addition of forskolin (5 μM) and IBMX (100 μM) in the presence of vehicle or cyclopamine-KAAD. Each data point is average of two to four cells. *n* = 6. \**P* \< 0.05 vs. vehicle by paired Student's *t* test. (*C*) Change in HCO~3~^−^ secretion measured as short-circuit current (∆Isc~HCO3-~) with addition of vehicle, SHH (53 nM), and SAG (200 nM). Data on *Left*, *n* = 9, \*\**P* \< 0.01 and \**P* \< 0.05 vs. vehicle by one-way repeated-measures ANOVA with Sidak multiple-comparison posttest. Data (*Right*) are from a different set of airway epithelia treated with vehicle or cyclopamine-KAAD (250 nM), *n* = 9, \**P* \< 0.05 by paired Student's *t* test. (*D*) ASL pH measured before (basal) and 30 min after addition of vehicle or SHH (53 nM). Connecting lines indicate paired epithelia from an individual donor. *n* = 6, \*\**P* \< 0.01 compared with basal by paired Student's *t* test. (*E*) ASL pH measured before and 45 min after addition of vehicle or cyclopamine-KAAD (250 nM) followed by addition of SHH. *n* = 6, \**P* \< 0.05 compared with basal and ^††^*P* \< 0.01 compared with vehicle, both by one-way repeated measures ANOVA with Sidak multiple-comparison posttest.](pnas.1719177115fig05){#fig05}

cAMP also regulates cAMP-dependent PKA, which phosphorylates and activates apical CFTR anion channels ([@r38]). CFTR secretes HCO~3~^−^, thereby regulating ASL pH ([@r39], [@r40]). Decreased HCO~3~^−^ secretion acidifies airway liquid, which reduces antimicrobial activity and increases mucus viscosity ([@r40], [@r41]). SHH and SAG reduced and cyclopamine-KAAD increased HCO~3~^−^ secretion ([Fig. 5*C*](#fig05){ref-type="fig"}). These changes were paralleled by acidification and alkalinization, respectively, of ASL ([Fig. 5 *D* and *E*](#fig05){ref-type="fig"}).

Discussion {#s5}
==========

These findings suggest that motile airway cilia serve as a HH signaling center. Thus, in addition to propelling particulate material out of the lung, motile cilia, like primary cilia, may have a sensory function. That conclusion is consistent with previous work showing that motile cilia on airway epithelial cells express bitter taste receptors that increase the intracellular Ca^2+^ concentration ([@r16]). Our results also identify a noncanonical signaling pathway that reduces cAMP levels in ciliated airway epithelial cells.

The HH signaling components and cAMP-dependent signaling proteins were both present in motile cilia. That close proximity may be key for efficient signal transduction, as is the case in primary cilia ([@r3], [@r42]). A ciliary location also positions HH signaling proteins in an optimal location to detect SHH moving through the thin layer of liquid covering the airway surface. Thus, apical HH signaling could involve both cell-autonomous signaling (an individual ciliated cell might release SHH and detect it) and noncell autonomous signaling (SHH released by one ciliated cell might be detected by a different ciliated cell some distance away). This contrasts with basolateral HH signaling, which is paracrine and may be more locally constrained. The apical location also makes HH signaling accessible to other substances in airway liquid and to inhaled therapeutics: for example the SMO agonist, fluticasone, prescribed for asthma ([@r43]).

Previous studies reported noncanonical HH signaling mediated through primary cilia. For example, SHH signaling regulates migration of murine embryo fibroblasts and tubulogenesis of endothelial cells in a GLI1-independent manner ([@r44], [@r45]). Previous work in cells with primary cilia has also shown that SMO, the transducer of SHH signaling, can couple with Gi subunits ([@r32], [@r33]), and Gα~i~ can inhibit adenylyl cyclase, thereby reducing cellular levels of cAMP ([@r46]).

These results may raise questions about the relationship between primary and motile cilia and HH signaling. Previous studies of vertebrate HH signaling showed that primary cilia are essential for canonical HH signaling ([@r3], [@r4], [@r47]). Our results now suggest a role for motile cilia in noncanonical HH signaling. In addition, a recent report suggested the HH signaling components localize odorant receptors in mouse olfactory cilia ([@r48]); olfactory cilia have a 9 + 2 axoneme, but lack dynein arms and are immotile ([@r30]). Thus, during evolution, HH signaling components and cilia may have been adapted for a variety of functions, with variations in cilia type and the function of HH signaling components. In this regard, SUFU, GLI2, and GLI3 are essential regulators in the canonical HH signaling pathway ([@r49], [@r50]), but their potential function in motile airway cilia remains unknown.

Airway injury and chronic lung diseases induce a variety of inflammatory, proliferative, and defense processes ([@r51], [@r52]). They can also increase SHH levels ([@r22], [@r51], [@r52]). Previous studies showed that SHH in the basolateral compartment may restrain responses to injury by reducing mesenchymal cell proliferation ([@r12]). Similarly, SHH in the apical compartment might restrain, at least in part, respiratory defense responses initiated by injury and disease. By reducing intracellular levels of cAMP, SHH might dampen defenses, including cilia beating and CFTR-mediated anion secretion. However, whereas HH signaling in mesenchymal cells is through primary cilia and the canonical HH signaling pathway, in epithelial cells it is through motile cilia and a noncanonical pathway.

Materials and Methods {#s6}
=====================

[*SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental) contains a detailed description of the materials and methods used.

Primary cultures of differentiated human airway epithelia were prepared from trachea and bronchi of nonsmokers, seeded onto collagen-coated semipermeable membranes, grown at the air--liquid interface, and studied after they had differentiated and at least 14 d after seeding ([@r53]).

We used standard immunocytochemistry methods. Primary and secondary antibodies are listed in [Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental). Samples were imaged by confocal microscopy and analyzed with NIH Fiji software. All studies were performed at least four times using epithelia prepared from different donors. Studies were approved by the University of Iowa Institutional Review Board.

Methods for transmission electron microscopy and quantitative RT-PCR ([Table S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1719177115/-/DCSupplemental)) were standard. The SHH assay used a reporter cell line. cAMP concentrations were measured by ELISA and with a FRET-based cAMP assay ([@r36]). CBF was measured with transmitted light line-scans. ASL pH and transepithelial HCO~3~^−^ secretion were measured as previously described ([@r40], [@r41]).

Statistical significance was tested with an unpaired or paired Student's *t* test for comparisons between two samples. For comparisons between more than two samples, statistical significance was tested with a one-way repeated-measures ANOVA with Sidak multiple-comparison posttest. *P* \< 0.05 was considered statistically significant.
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